RecruitingNot ApplicableNCT07677774

GPC3-Targeted PET/CT in Hepatocellular Carcinoma

Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma

Sponsor

The First Affiliated Hospital of Xiamen University

Enrollment

40 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma (HCC)Glypican-3 GPC3-targeted PET/CT

Summary

The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with 18F-FDG PET/CT.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying 18F-FDG PET/CT and GPC3-targeted PET/CT for people with gpc3-targeted pet/ct, glypican-3, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.